Genomtec S.A. (4VI.F)

2,6150 0,0000 (0,00%) Börsenschluss: 09:59AM CEST

Genomtec S.A.

Bierutowska Street 57-59
WROCLAW BUSINESS PARK 3
Wroclaw 51-317
Poland
48 793 440 931
https://www.genomtec.com

Sektor(en): Healthcare
Branche: Medical Devices
Vollzeitmitarbeiter: 18

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Miron Tokarski Ph.D.	Co-Founder, CEO & Member of the Management Board	N/A	N/A	N/A
Mr. Henryk Roguszczak	Co-founder & Chief Designer	N/A	N/A	N/A
Dr. Malgorzata Malodobra-Mazur	Co-founder and Director of Research & Development	N/A	N/A	N/A
Michal Wachowski	CFO & Member of the Management Board	N/A	N/A	N/A
Dr. Charles Winiarski	Chief Operating Officer	N/A	N/A	N/A
Charudutt Shah	Chief Business Officer & Member of the Management Board	N/A	N/A	N/A
Mr. Jason Reece	Chief Technology Officer	N/A	N/A	N/A
Magdalena Kicinska	Chief Marketing Officer	N/A	N/A	N/A
Mr. Jarek Oleszczuk M.D., Ph.D.	C.B.O	N/A	N/A	N/A
Boleslaw Winiarski Ph.D.	Chief Product Officer	N/A	N/A	N/A

Die Beträge haben den Stand und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Genomtec S.A. researches, develops, manufactures, and commercializes innovative molecular diagnostic products in optical systems and isothermal nucleic acid amplification methods in Poland and internationally. The company develops Genomtec ID, a technological device that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analyzing the biological material of patients using swabs, urine samples, saliva, blood, and other body fluids. It also develops Genomtec Tumor, a SNAAT based solution used to identify neoplastic mutations and mutations with prognostic value in neoplastic disease; Genomtec SARS-CoV-2 EvaGreen and Direct-RT-LAMP CE-IVD Kit to detect SARS-CoV-2 RNA in various biological samples from patients with suspected COVID-19 infection; and Genomtec RT-LAMP CE-IVD Duo-Kit for the detection of all variants of the SARS-CoV-2 virus. Genomtec S.A was founded in 2016 and is based in Wroclaw, Poland.

Corporate Governance

Genomtec S.A.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.